The Types segmentation classifies Filariasis Treatment products into three principal categories: Monotherapy Antifilarials, Combination Therapies, and Emerging Molecular Entities. Monotherapy Antifilarials consist of single‑active agents such as diethylcarbamazine (DEC), ivermectin, and albendazole, which dominate current usage due to established efficacy and regulatory approval; they generate the bulk of sales volume. Combination Therapies integrate two or more antifilarial agents (e.g., ivermectin + albendazole) to enhance therapeutic outcomes and reduce resistance risk, contributing a significant share of market value despite higher pricing. Emerging Molecular Entities refer to novel compounds under clinical investigation or recently launched, targeting alternative pathways or offering improved safety profiles; this niche segment, while presently modest in size, is poised for accelerated growth as pipeline products advance. Together, these type categories define the Filariasis Treatment segmentation, each influencing the market’s total addressable size through distinct pricing structures, adoption rates, and development pipelines.